CheckMan Stock Market Overview

VettaFi's Head of Research Todd Rosenbluth discussed the SPDR S&P Insurance ETF (KIE) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and analysis, visit VettaFi | ETF Trends.

Tech firm released early versions of its latest large language model and a real-time image generator as it tries to catch up to OpenAI

The Invesco Financial Preferred ETF offers higher yield and lower volatility compared to common stock, making it a potential asset for portfolios. The PGF ETF primarily invests in fixed-rate preferred securities issued by financial entities in the U.S. domestic market. The fund's sector-specific focus on the financial sector exposes it to sector-specific risks, but it also provides an opportunity for steady dividend payments.

Snap-on (SNA) reports lower sales in first-quarter 2024 on decline in sales across the Commercial & Industrial Group and Tools Group segments.

Alphabet Inc (NASDAQ:GOOG) is expected to surpass Street expectations when it reports its earnings after market on April 25. The tech giant should outperform revenue estimates, particularly in the search and YouTube segments, according to Bank of America.

Ibotta had a strong debut on the New York Stock Exchange on Thursday, soaring as much as 34% above their initial public offering (IPO) price.  The company sold 6.6 million shares at $88 each raising $577.3 million, above its earlier price range of $76 to $84 per share.

Virtu Financial's (VIRT) Q1 results are likely to suffer from weakness in Execution Services segment and lower net trading income, partly offset by improved interest and dividends income.

Marsh & McLennan's (MMC) first-quarter results benefit on the back of solid Marsh business and higher revenues derived from Health and Wealth businesses, partly offset by higher compensation and benefits expenses.

Kitco News - Investors still haven't made the link between high gold prices and mining equities, said Robert Quartermain, co-chairman of Dakota Gold.

Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary platforms to create multispecific antibody therapeutics and antibody-drug conjugate technologies for its drug candidates.